Biocon secures USFDA approval for Pebrilzo
Statements (5)
- Bullish
Biocon received European Commission market authorization for a biosimilar for breast cancer treatment.
- Neutral
Biocon's pertuzumab is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency's new tailored clinical approach
- Bullish
Biocon secures U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay) Injection, a biosimilar to Perjeta®.
- Bullish
Biocon shares gain after US FDA approves cancer drug biosimilar
- Bullish
Biocon received USFDA approval for Pebrilzo, its fifth cancer biosimilar